Novartis scraps mid-stage radiopharma asset as Pluvicto soars

negativePluvictoDiscontinued radiopharma assetNegative

AI Analysis

Summary

Novartis discontinued a mid-stage radiopharma asset being developed for breast cancer and solid tumors following disappointing clinical data. The company continues to advance Pluvicto, its radioactive therapy candidate.

Outcome Details

Mid-stage radiopharma asset discontinued due to disappointing trial data

Importance:4/10

Sentiment:

-0.60

drug discontinuationradiopharmabreast cancersolid tumorsfailed development

Related Companies

$NVS

Read the original article

Published by BioSpace on July 22, 2026 11:32 AM

Read Original